COMPANY

Akava Therapeutics

AKAVA Therapeutics was established in 2019 as a commercialization arm for the pipeline of compounds developed from the Silverman lab at Northwestern University. From company website Source · Oct 12, 2026

Keywords: oncology neurology amyotrophic lateral sclerosis neurodegenerative diseases melanoma

Location: Winnetka, IL · source · Feb 19, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Filed a Form D for an offering of up to $15M, no sales reported yet (filed Feb 19, 2026). SEC Form D 0001966649-26-000001 (Feb 19, 2026)
Evidence (1 event)
- Feb 19, 2026 · SEC Form D 0001966649-26-000001
  Name of Issuer: Akava Therapeutics Inc.; CIK: 1966649; Address: Winnetka, IL; Submission type: D; Filing date: 2026-02-19; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 0; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals